Conclusion

The reduction in toxicity due to ablative regimens is not likely to diminish by the development of new ablative programs. In fact, there are few examples of truly new ablative regimens. Rather, better understanding of the pathophysiology of RRTs will lead to new approaches for their prevention and treatment. Development of newer immunosuppressive regimens, such as the combination of tacrolimus or cyclosporine with mycophenolate mofetil, is likely to make a much greater impact on toxicity than changes in the ablative program itself.

10. Bearman SI, Petersen FB, Schor RA, et al.: Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 5:173-177, 1990.

11. Murdych T, Weisdorf DJ: Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 28:283-287, 2001.

12. Kupari M, Volin L, Suokas A, et al.: Cardiac involvement in bone marrow transplantation: electrocardio-graphic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 5:91-98, 1990.

13. Quezado ZMN, Wilson WH, Cunnion RE, et al.: Highdose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Int Med 118:31-36, 1993.

14. Morandi P, Ruffini PA, Benvenuto GM, et al.: Serum cardiac troponin I levels and ECG/echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant 28:277-282, 2001.

15. Cardinale D, Sandri MT, Colombo A, et al.: Prognostic value of troponin 1 in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754, 2004.

16. Morandi P, Ruffini PA, Benvenuto GM, et al.: Serum cardiac troponin I levels and ECG/echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant 28:277-282, 2001.

17. Sanchorawala V, Wright DG, Seldin DC, et al.: An overview of the use of high-dose melphalan with autol-ogous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28:637-642, 2001.

18. Gertz MA, Lacy MQ, Gastineau DA, et al.: Blood stem cell transplantation as therapy for primary systemic amy-loidosis (AL). Bone Marrow Transplant 26:963-969, 2000.

19. Moreau P, Leblond V, Bourquelot P, et al.: Prognostic factors for survival and response ater high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101:766-769, 1998.

20. Comenzo RL, Sanchorawala V, Fisher C, et al.: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM + G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Brit J Haematol 104:553-559, 1999.

21. Woo SB, Sonis ST, Monopoli MM, et al.: A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72:1612-1617, 1993.

22. Pico JL, Avila-Garavito A, Naccahie P: Mucositis: its occurance, consequences, and treatment in the oncology setting. Oncologist 3:446-451, 1998.

23. Bellm LA, Epstein JB, Rose-Ped A, et al.: Patient reports of complications of bone marrow transplantation. Supp Care Cancer 8:33-39, 2000.

24. Stiff P: Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 27(suppl 2):S3-S11, 2001.

25. Horowitz MM, Oster G, Fuchs H, et al.: Oral Mucositis Assessment Scale (OMAS) as a predictor of clinical and economic outcomes in bone marrow transplant patients. Blood 94(suppl 1):399a, 1999.

26. Fox AD, Kripke SA, De Paula J, et al.: Effect of a gluta-mine suppled enteral diet on methotrexate-induced enterocolitis. JParrenter Enteral Nutr 12:325-331, 1988.

27. O'Dwyer ST, Scott T, Smith RJ, et al.: 5-Fluorouracil toxicity on small intestine but not white blood cells is decreased by glutamine. Clin Res 35:367a, 1987.

28. Anderson PM, Ramsay NK, Shu XO, et al.: Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22:339-344, 1998.

29. Coghlin Dickson TM, Wong RM, Offrin RS, et al.: Effect of oral glutamine supplation during bone marrow transplantation. JParenter Enteral Nutr 24: 61-66, 2000.

30. Huang EY, Leung SW, Wang CJ, et al.: Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46: 535-539, 2000.

31. Nemunitis J, Rosenfeld CS, Ash R, et al.: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15:949-954, 1995.

32. Atkinson K, Biggs JC, Downs K, et al.: GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes, and lymphocytes. Aust NZ J Med 21:686-692, 1991.

33. Schwerkoske J, Schwartzberg L, Weaver C, et al.: A phase I, double-masked, placebo-controlled study to evaluate tolerability of Neumega (rh IL-11; opreleukin) to reduce mucositis in patient with solid tumor or lymphoma receiving high dose chemotherpay with autolo-gous peripheral blood stem cell reinfusion. Proc Am Soc Clin Oncol 18:584a, 1999.

34. Antin JH, Lee SJ, Neuberg D, et al.: A phase I/II doubleblind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD preven tion in allogeneic stem cell transplantation. Bone Marrow Transplant 29:373-377, 2002.

35. Rubin JS, Osada H, Finch PW, et al.: Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Nat Acad Sci USA 86:802-806, 1989.

36. Rubin JS, Bottaro DB, Chedid M, et al.: Keratinocyte growth factor. Cell Biol Int 19:399-411, 1995.

37. Farrell CL, Bready JV, Rex KL, et al.: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933-939, 1998.

38. Farrell CL, Rex KL, Kaufman SA, et al.: Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 75:609-620, 1999.

39. Spielberger R, Emmanouilides C, Stiff P, et al.: Use of recombinant human keratinocyte growth factor can reduce severe oral mucositis in patients with hemato-logic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation-based conditioning—results of a phase 3 trial. Proc Am Soc Clin Oncol 22:3642, 2003.

40. Vesole DH, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloabla-tive chemotherapy. Blood 94(suppl 1):154a, 1999.

41. Giles FJ, Rodriguez R, Weisdorf D, et al.: A phase III, randomized, double-blind, placebo-controlled, study of iseganen for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 28:559-565, 2004.

42. Yuhas JM, Culo F: Selective inhibition of the nephro-toxicity of cisdichlorodiammineplatinum (II) by WR-2721 without altering its antitumor activity. Cancer Treat Rep 64:57-64, 1980.

43. Valeriote F, Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4341, 1982.

44. Phillips GL, Meisenburg B, Hale GA, et al.: Amifostine cytoprotection of escalating doses of melphalan and autologous hematopoietic stem cell transplantation: final results of a phase I & II study. Proc Am Soc Clin Oncol 20:24, 2001.

45. Thumma S, Hari P, Bredeson C, et al.: Phase I/II trial of dose escalation of melphalan with amifostine cytopro-tection supported by autologous hematopoietic stem cell transplant in multiple myeloma patients > 65 years. Blood 102(suppl 1);3663, 2003.

46. Fox-Geiman MP, Fisher SG, Kiley K, et al.: Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emeto-genic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 7:596-603, 2001.

47. Lacerda JF, Martins C, Carmo JA, et al.: Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc 32:2680-2681, 2000.

48. Eagle DA, Gian V, Lauwers GY, et al.: Gastroparesis following bone marrow transplantation. Bone Marrow Transplant 28:59-62, 2001.

49. Navari RM: Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 1:89-103, 2003.

50. McDonald GB, Hinds MS, Fisher LB, et al.: Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255-267, 1993.

51. Shulman HM, Fisher LB, Schoch HG, et al.: Venocclusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms. Hepatology 19:1171-1180, 1994.

52. Strasser SI, McDonald GB, Schoch HG, et al.: Severe hepatocellular injury after hematopoietic cell transplant: incidence and etiology in 2136 consecutive patients. Hepatology 32:299, 2000.

53. Salat C, Holler E, Reinhardt B, et al.: Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 14:747-750, 1994.

54. Salat C, Holler E, Kolb H-J, et al.: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 89:2184-2188, 1997.

55. Testa S, Manna A, Porcellini A: Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 18:383-388, 1996.

56. Fried MW, Duncan A, Seroka S, et al.: Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 27:635-639, 2001.

57. DeLeve LD: Cellular target of cyclophosphamide toxic-ity in murine liver: role of glutathione and site of metabolic activation. Hepatology 24:830-837, 1996.

58. Slattery JT, Kalhorn TF, McDonald GB: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484-1494, 1996.

59. DeLeve LD, Wang X: Role of oxidative stress and glu-tathione in busulfan toxicity in cultured murine hepa-tocytes. Pharmacology 60:143-154, 2000.

60. Meresse V, Hartmann O, Vassal G, et al.: Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 10:135-141, 1992.

61. Andersson BS, Kashyap A, Gian V, et al.: Conditioning therapy with intravenous busulfan and cyclophos-phamide (IV Bu CY2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8:145-154, 2002.

62. Zager RA: Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46:1443-1458, 1994.

63. Radich JP, Sanders JE, Buckner CD, et al.: Second allo-geneic marrow transplantation for patients with recurrent leukemia after initial transplantation with total-body irradiation-containing regimens. J Clin Oncol 11:304-313, 1993.

64. Tanikawa S, Mori S, Ohhashi K, et al.: Predictive markers for hepatic veno-occlusive disease after hematopoi-etic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 26:881-886, 2000.

65. Rio B, Bauduer F, Arrago JP: N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 11:471-472, 1993.

66. Richard S, Seigneur M, Blann A, et al.: Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant 18:955-959, 1996.

67. Carreras E, Bertz H, Arcese W, et al.: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92:3599-3604, 1998.

68. Giles FJ, Kantarjian HM, Kornblau SM, et al.: MylotargTM (gemtuzumab ozogamicin) therapy is associated with hepatic venooclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-413, 2001.

69. Sievers EL, Larson RA, Stadtmauer, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001.

70. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 99:2310-2314, 2002.

71. Wadleigh M, Richardson PG, Zahrieh D, et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102:1578-1582, 2003.

72. Grinsky T, Benhamou E, Bourhis J-H, et al.: Prospective randomized comparison of single-dose versus hyper-fractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 18:981-986, 2000.

73. Anderson JE, Appelbaum FR, Schoch G, et al.: Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biol Blood Marrow Transplant 7:163-170, 2001.

74. Essell JH, Schroeder MT, Harman GS, et al.: Ursodiol prophylaxis against hepatic complications of allo-geneic bone marrow transplantation. Ann Intern Med 128:975-981, 1998.

75. Ohashi K, Tanabe J, Watanabe R, et al.: The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol J 64:32-38, 2000.

76. Hagglund H, Ringden O, Ericzon BG, et al.: Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 62:1076-1080, 1996.

77. Richardson PG, Murakami C, Jin Z, et al.: Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100:4337-4343, 2002.

78. Richardson PG, Soiffer RJ, Antin JH, et al.: Defibrotide for the treatment of severe veno-occlusive disease and multi-system organ failure post SCT. Final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings. Blood 104(suppl 1):360, 2004.

79. Ringden O, Remberger M, Lehmann S, et al.: N-acetyl-cysteine for hepatic veno-occlusive disease after allo-geneic stem cell transplantation. Bone Marrow Transplant 25:993-996, 2000.

80. Goringe AP, Brown S, O'Callaghan U, et al.: Glutamine and vitamin E in the treatment of hepatic veno-occlu-sive disease following high-dose chemotherapy. Bone Marrow Transplant 21: 829-832, 1998.

81. Brown SA, Goringe A, Fegan C, et al.: Parenteral gluta-mine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 22:281-284, 1998.

82. Murray JA, LaBrecque DR, Gingrich RD, et al.: Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with a side-to-side portacaval shunt. Gastroenterol 92:1073-1077, 1987.

83. Nimer SD, Milewicz AL, Champlin RE, et al.: Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 49:819-821, 1990.97.

84. Rapaport AP, Doyle HR, Starzl T, et al.: Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 8:421-424, 1991.

85. Zager RA, O'Quigley J, Zager BK, et al.: Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 13:210-216, 1989.

86. Lawton CA, Barber-Derus SW, Murray JK, et al.: Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte depleted bone marrow transplantation in adult patients. Int J Rad Oncol Biol Phys 23:681-686, 1992.

87. Singh N, Gayowski T, Marino JR: Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 9: 68-75, 1996.

88. Woo M, Przepiorka D, Ippoliti C, et al.: Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 20:1095-1098, 1997.

89. Benito AI, Furlong T, Martin PJ, et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924-1929, 2001.

90. Furlong T, Storb R, Anasetti C, et al.: Clinical outcome after conversion to FK506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 26:985-991, 2000.

91. Phillips GL, Meisenberg B, Hale GA, et al.: Amifostine cytoprotection of escalating doses of melphalan and autologous hematopoietic stem cell transplantation: final results of a phase I and II study. Proc Am Soc Clin Oncol 20:24, 2001.

92. Hartmann JT, von Vangerow A, Fels LM, et al.: A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Brit J Cancer 84:313-320, 2001.

93. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 1: 28-36, 2000.

94. Badros A, Barlogie B, Siegel E, et al.: Results of autolo-gous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114:822-829, 2001.

95. Dember LM, Sanchorawala V, Seldin DC, et al.: Effect of dose-intensive intravenous melphalan and autolo-gous blood stem-cell transplantation on AL amyloido-sis-associated renal disease. Ann Intern Med 134:746-753, 2001.

96. Sezer O, Schmid P, Shweigert M, et al.: Rapid reversal of nephrotic syndrome due to primary systemic AL amy-loidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 23:967-969, 1999.

97. Vassal G, Deroussent A, Hartmann O, et al.: Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50:6203-6207, 1990.

98. Grigg AP, Shepherd JD, Phillips GL: Busulphan and phenytoin. Ann Intern Med 111:1149-1150, 1989.

99. Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 7:1563-1568, 1989.

100. Rubin EH, Anderson JW, Berg DT, et al.: Risk factors for high-dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol 10:948-953, 1992.

101. Smith GA, Damon LE, Rugo HS, et al.: High-dose cytarabine dose modification reduces the incidence of neurotoxocity in patients with renal insufficiency.

J Clin Oncol 15:833-839, 1997.

102. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65(suppl):89-98, 1981.

103. Thompson CB, Sander JE, Flournoy N, et al.: The risks of central nervous system relapse and leukoen-cephalopathy in patients receiving bone marrow transplants for acute leukemia. Blood 67:195-199, 1986.

104. Bechstein WO: Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 13:313-326, 2000.

105. Phipps S, Dunavant M, Srivastava DK, et al.: Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 18:1004-1011, 2000.

106. Andrykowski MA, Altmaier EM, Barnett RL, et al.: Cognitive dysfunction in adult survivors of allogeneic marrow transplantation: relationship to dose of total body irradiation. Bone Marrow Transplant 6:269-276, 1990.

107. Stemmer SM, Cagnoni PJ, Shpall EJ, et al.: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 14:1463-1472, 1996.

108. Doroshow JH, Synold T, Somlo G et, al.: High-dose infusional paclitaxel (P), platinum (DDP), cyclophos-phamide (CY), and cyclosporine A (CSA) with peripheral blood progenitor cell rescue for high risk primary and responsive metastatic breast cancer. Proc Am Soc Clin Oncol 16:235, 1997.

109. Mayordomo JI, Yubero A, Cajal R, et al.: Phase I trial of high-dose paclitaxel in combination with cyclophos-phamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue. Proc Am Soc Clin Oncol 16:102, 1997.

110. Gluck S, Arnold A, Dulude H, et al.: High-dose cyclophosphamide, mitoxantrone and paclitaxel with blood progenitor cell support for the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:137, 1996.

111. Vahdat L, Papadopoulos K, Balmaceda C, et al.: Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophos-phamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res 4:1689-1695, 1998.

112. Nieto Y, Cagnoni PJ, Shpall EJ, et al.: Phase I trial of docetaxel (DTX) (Taxotere) with peripheral blood progenitor cell (PBPC) support, with melphalan (MEL) and carboplatin (CB), in refractory advanced cancer. Proc Am Soc Clin Oncol 19:217, 2000.

113. Papadopoulos KP, Egorin MJ, Huang M, et al.: The pharmacokinetics and pharmacodynamics of highdose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol 47:45-50, 2001.

114. Thomas AE, Patterson J, Prentice HG, et al.: Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone Marrow Transplant 1:347-355, 1987.

115. Hows JW, Mehta A, Ward L, et al.: Comparison of mesna with forced diuresis to prevent cyclophos-phamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomized study. Brit J Cancer 50:753-756, 1984.

116. Vose JM, Reed EC, Pippert GC, et al.: Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 11:1306-1310, 1993.

117. Bedi A, Miller CB, Hanson JL, et al.: Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 13:1103-1109, 1995.

118. Ringdén O, Ruutu, T, Remberger M, et al.: A randomized trial comparing busulfan versus total body irradiation in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83:2723-2730, 1994.

119. Ringdén O, Ruutu T, Remberger M, et al.: A randomized trial comparing busulfan versus total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant Proc 26:1831-1832, 1994.

120. Leung AYH, Suen CKM, Lie AKW, et al.: Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98:1972-1978, 2001.

121. Arthur RR, Shah KV, Baust SJ, et al.: Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl JMed 315: 230-234, 1986.

122. Apperly JF, Rice SJ, Bishop JA, et al.: Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation 43:108-112, 1987.

123. Chan PK, Ip KW, Shiu SY, et al.: Association between polyomaviruria and microscopic haematuria in bone marrow transplant recipients. J Infect 29:139-146, 1994.

124. Bogdanovic G, Priftakis P, Giraud G, et al.: Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol 42:5394-5396, 2004.

125. Akiyama H, Kurosu T, Sakashita C, et al.: Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis 32:1325-1330, 2001.

126. Shrom SH, Donaldson MH, Duckett JW, et al.: Formalin treatment for intractable hemorrhagic cystitis. A review of the literature with 16 additional cases. Cancer 38: 1785-1789, 1976.

127. Trigg ME, O'Reilly J, Rumelhart S, et al.: Prostaglandin Ej bladder instillations to control severe hemorrhagic cystitis. J Urol 143:92-94, 1990.

128. Efros MD, Ahmed T, Coombe N, et al.: Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology 43:355-360, 1994.

129. Lapides J: Treatment of delayed intractable hemor-rhagic cystitis following radiation or chemotherapy. J Urol 104:707-708, 1970.

130. Baronciani D, Angelucci E, Erer B, et al.: Suprapubic cystotomy as treatment for severe hemorrhagic cystitis after bone marrow transplantation. Bone Marrow Transplant 16:267-270, 1995.

131. Gine E, Rovira M, Real I, et al.: Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant 31:923-925,

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment